Thursday, September 15, 2016

Advair Diskus


See also: Generic Advair HFA


Advair Diskus is a brand name of fluticasone/salmeterol, approved by the FDA in the following formulation(s):


ADVAIR DISKUS 100/50 (fluticasone propionate; salmeterol xinafoate - powder; inhalation)



  • Manufacturer: GLAXOSMITHKLINE

    Approval date: August 24, 2000

    Strength(s): 0.1MG/INH;EQ 0.05MG BASE/INH [RLD]


  • Manufacturer: GLAXOSMITHKLINE

    Approval date: August 24, 2000

    Strength(s): 0.25MG/INH;EQ 0.05MG BASE/INH [RLD]


  • Manufacturer: GLAXOSMITHKLINE

    Approval date: August 24, 2000

    Strength(s): 0.5MG/INH;EQ 0.05MG BASE/INH [RLD]

Has a generic version of Advair Diskus been approved?


No. There is currently no therapeutically equivalent version of Advair Diskus available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Advair Diskus. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Inhalation device
    Patent 5,590,645
    Issued: January 7, 1997
    Inventor(s): Davies; Michael B. & Hearne; David J. & Rand; Paul K. & Walker; Richard I.
    Assignee(s): Glaxo Group Limited
    An inhalation device is described for use with a medicament pack in which at least one container for medicament in powder form is defined between two sheets peelably secured to one another. The device comprises means for peeling the sheets apart at an opening station to open the container; and an outlet, communicating with the opened container, through which a user can inhale medicament in powder form from the opened container.
    Patent expiration dates:

    • September 1, 2011
      ✓ 
      Pediatric exclusivity




  • Inhalation device
    Patent 5,860,419
    Issued: January 19, 1999
    Inventor(s): Davies; Michael Birsha & Hearne; David John & Rand; Paul Kenneth & Walker; Richard Ian
    Assignee(s): Glaxo Group Limited
    An inhalation device is described for use with a medicament pack in which at least one container for medicament in powder form is defined between two sheets peelably secured to one another. The device comprises means for peeling the sheets apart at an opening station to open the container; and an outlet, communicating with the opened container, through which a user can inhale medicament in powder form from the opened container.
    Patent expiration dates:

    • September 1, 2011
      ✓ 
      Pediatric exclusivity




  • Inhalation device
    Patent 5,873,360
    Issued: February 23, 1999
    Inventor(s): Davies; Michael Birsha & Hearne; David John & Rand; Paul Kenneth & Walker; Richard Ian
    Assignee(s): Glaxo Group Limited
    An inhalation device is described for use with a medicament pack in which at least one container for medicament in powder form is defined between two sheets peelably secured to one another. The device comprises means for peeling the sheets apart at an opening station to open the container; and an outlet, communicating with the opened container, through which a user can inhale medicament in powder form from the opened container.
    Patent expiration dates:

    • February 23, 2016
      ✓ 
      Drug product


    • August 23, 2016
      ✓ 
      Pediatric exclusivity




  • Inhalation device
    Patent 6,032,666
    Issued: March 7, 2000
    Inventor(s): Davies; Michael Birsha & Hearne; David John & Rand; Paul Kenneth & Walker; Richard Ian
    Assignee(s): Glaxo Group Limited
    An inhalation device is described for use with a medicament pack in which at least one container for medicament in powder form is defined between two sheets peelably secured to one another. The device comprises means for peeling the sheets apart at an opening station to open the container; and an outlet, communicating with the opened container, through which a user can inhale medicament in powder form from the opened container.
    Patent expiration dates:

    • September 1, 2011
      ✓ 
      Pediatric exclusivity




  • Inhalation device
    Patent 6,378,519
    Issued: April 30, 2002
    Inventor(s): Michael Birsha; Davies & David John; Hearne & Paul Kenneth; Rand & Richard Ian; Walker
    Assignee(s): Glaxo Group Limited
    An inhalation device is described for use with a medicament pack in which at least one container for medicament in powder form is defined between two sheets peelably secured to one another. The device comprises means for peeling the sheets apart at an opening station to open the container; and an outlet, communicating with the opened container, through which a user can inhale medicament in powder form from the opened container.
    Patent expiration dates:

    • September 1, 2011
      ✓ 
      Pediatric exclusivity




  • Inhalation device
    Patent 6,536,427
    Issued: March 25, 2003
    Inventor(s): Michael Birsha; Davies & David John; Hearne & Paul Kenneth; Rand & Richard Ian; Walker & James Barry Douglas; Palmer
    Assignee(s): Glaxo Group Limited
    An inhalation device is described for use with a medicament pack in which at least one container for medicament in powder form is defined between two sheets peelably secured to one another. The device comprises means for peeling the sheets apart at an opening station to open the container; and an outlet, communicating with the opened container, through which a user can inhale medicament in powder form from the opened container.
    Patent expiration dates:

    • September 1, 2011
      ✓ 
      Pediatric exclusivity




  • Inhalation device
    Patent 6,792,945
    Issued: September 21, 2004
    Inventor(s): Michael Birsha; Davies & David John; Hearne & Paul Kenneth; Rand & Richard Ian; Walker
    Assignee(s): Glaxo Group Limited
    An inhalation device is described for use with a medicament pack in which at least one container for medicament in powder form is defined between two sheets peelably secured to one another. The device comprises means for peeling the sheets apart at an opening station to open the container; and an outlet, communicating with the opened container, through which a user can inhale medicament in powder form from the opened container.
    Patent expiration dates:

    • September 1, 2011
      ✓ 
      Pediatric exclusivity




  • Inhalation device
    Patent 7,225,808
    Issued: June 5, 2007
    Inventor(s): Davies; Michael Birsha & Hearne; David John & Rand; Paul Kenneth & Walker; Richard Ian
    Assignee(s): Glaxo Group Limited
    An inhalation device is described for use with a medicament pack in which at least one container for medicament in powder form is defined between two sheets peelably secured to one another. The device comprises means for peeling the sheets apart at an opening station to open the container; and an outlet, communicating with the opened container, through which a user can inhale medicament in powder form from the opened container.
    Patent expiration dates:

    • September 1, 2011
      ✓ 
      Pediatric exclusivity




  • Inhalation device
    Patent 7,389,775
    Issued: June 24, 2008
    Inventor(s): Davies; Michael Birsha & Hearne; David John & Rand; Paul Kenneth & Walker; Richard Ian
    Assignee(s): Glaxo Group Limited
    An inhalation device is described for use with a medicament pack in which at least one container for medicament in powder form is defined between two sheets peelably secured to one another. The device comprises means for peeling the sheets apart at an opening station to open the container; and an outlet, communicating with the opened container, through which a user can inhale medicament in powder form from the opened container.
    Patent expiration dates:

    • September 1, 2011
      ✓ 
      Pediatric exclusivity



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • April 30, 2011 - MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION AND REDUCING EXACERATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

    • March 31, 2012 - STUDY INFORMATION ADDED TO LABEL REGARDING BONE MINERAL DENSITY

See also...

  • Advair Consumer Information (Drugs.com)
  • Advair Diskus Powder Consumer Information (Wolters Kluwer)
  • Advair Diskus Consumer Information (Cerner Multum)
  • Advair Advanced Consumer Information (Micromedex)
  • Advair Diskus Advanced Consumer Information (Micromedex)
  • Advair Diskus 100/50 Advanced Consumer Information (Micromedex)
  • Advair Diskus 250/50 Advanced Consumer Information (Micromedex)
  • Advair Diskus 500/50 Advanced Consumer Information (Micromedex)
  • Fluticasone/Salmeterol Inhaler Consumer Information (Wolters Kluwer)
  • Fluticasone/Salmeterol Powder Consumer Information (Wolters Kluwer)
  • Fluticasone and salmeterol Consumer Information (Cerner Multum)
  • Fluticasone and salmeterol Inhalation, oral/nebulization Advanced Consumer Information (Micromedex)

No comments:

Post a Comment